Cynosure Lutronic, one of the world’s leading energy-based medical device (EBD) companies, said its newly launched monopolar radiofrequency (RF) device, XERF, has received regulatory approval from Health Canada.

With this approval, XERF is now cleared for clinical use in Canada for facial contouring and wrinkle reduction, eyebrow lifting, and treatment of skin laxity in the face and neck. The company stated that the clearance marks a significant step toward strengthening its footprint in the North American aesthetic device market.

XERF is the first product launched following the merger of U.S.-based Cynosure and Korea’s Lutronic.

The device features a dual-monopolar RF configuration, combining the commonly used 6.78 MHz frequency with an additional 2 MHz setting, allowing for three adjustable depth levels during treatment.

A cooling gas is sprayed during procedures, enabling treatment without the need for anesthesia in most cases.

Another key innovation is the patent-pending Spider Pattern Technology, applied to the XERF effector. This large 20 x 30 mm applicator enables energy delivery across a broader surface area per shot, significantly enhancing treatment efficiency.

XERF is currently available in Korea, Japan, and Hong Kong.

The device is scheduled for official launch in Canada this June, following its Health Canada clearance. Cynosure Lutronic is also preparing to roll out the product in additional global markets, including the Philippines, Singapore, Vietnam, the U.S., and Brazil by the end of this year.

“Within just five months of launch in Korea, over 100 units have been contracted,” a Cynosure Lutronic official said. “Based on this strong demand, we anticipate similar success in Canada and other North American markets.”